31.33

0.26% 0.08

Pre-market: 31.29 -0.04 -0.13%

Zenas Biopharma Inc (ZBIO)

Overview News Price History Discussions Forecast

Zenas Biopharma Inc stock is traded at $31.33, with a volume of 425.16K. It is up +0.26% in the last 24 hours and up +43.98% over the past month. Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.

Previous Close:

$31.25

Open:

$31.17

24h Volume:

425.16K

Relative Volume:

1.20

Market Cap:

$1.32B

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

-1.48%

1M Performance:

+43.98%

6M Performance:

+162.84%

1Y Performance:

+53.05%

1-Day Range:

$30.30

$31.56

1-Week Range:

$26.88

$32.00

52-Week Range:

$5.83

$34.33

Zenas Biopharma Inc Stock (ZBIO) Company Profile

Name

Zenas Biopharma Inc

Sector

Healthcare (1136)

Industry

Biotechnology (633)

Phone

857-271-2954

Address

852 WINTER STREET, SUITE 250, WALTHAM

Employee

130

Twitter

Next Earnings Date

Latest SEC Filings

ZBIO's Discussions on Twitter

Compare ZBIO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ZBIO Zenas Biopharma Inc	31.33	1.47B	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	426.00	109.11B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	642.25	68.50B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	434.07	60.25B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	826.28	50.39B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	186.23	40.44B	447.02M	-1.18B	-868.57M	-6.1812

Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-20-25	Initiated	Wedbush	Outperform
Feb-04-25	Initiated	Wolfe Research	Outperform
Dec-16-24	Initiated	H.C. Wainwright	Buy
Nov-05-24	Initiated	Rodman & Renshaw	Buy
Oct-08-24	Initiated	Citigroup	Buy
Oct-08-24	Initiated	Guggenheim	Buy
Oct-08-24	Initiated	Jefferies	Buy
Oct-08-24	Initiated	Morgan Stanley	Overweight

View All

Zenas Biopharma Inc Stock (ZBIO) Latest News

Nov 03, 2025

Will Zenas BioPharma Inc. benefit from macro trendsMarket Rally & Long-Term Safe Investment Ideas - newser.com

Nov 03, 2025

Is Zenas BioPharma Inc. stock a dividend growth opportunityPortfolio Return Report & Real-Time Stock Movement Alerts - newser.com

Nov 03, 2025

How risky is Zenas BioPharma Inc. stock nowEarnings Risk Report & Real-Time Volume Spike Alerts - newser.com

Nov 03, 2025

What dividend safety score for Zenas BioPharma Inc. stockJuly 2025 Summary & Stock Timing and Entry Methods - newser.com

Nov 03, 2025

Will Zenas BioPharma Inc. stock sustain high P E ratios2025 Performance Recap & AI Powered Buy and Sell Recommendations - newser.com

Nov 03, 2025

Price momentum metrics for Zenas BioPharma Inc. explainedWeekly Market Report & Reliable Price Breakout Signals - newser.com

Nov 03, 2025

How to track smart money flows in Zenas BioPharma Inc.Dollar Strength & Fast Entry High Yield Stock Tips - newser.com

Nov 03, 2025

Multi asset correlation models including Zenas BioPharma Inc.2025 Price Momentum & Weekly Hot Stock Watchlists - newser.com

Nov 03, 2025

Nov 02, 2025

How to build a dashboard for Zenas BioPharma Inc. stockJuly 2025 Volume & Real-Time Stock Price Movement Reports - newser.com

Nov 02, 2025

Applying chart zones and confluence areas to Zenas BioPharma Inc.July 2025 Closing Moves & Reliable Volume Spike Trade Alerts - newser.com

Nov 02, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Nov 02, 2025

How Zenas BioPharma Inc. stock reacts to inflationary pressuresMarket Growth Review & Low Risk Entry Point Tips - newser.com

Nov 02, 2025

Has Zenas BioPharma Inc. formed a bullish divergenceTrade Analysis Report & Weekly Momentum Picks - newser.com

Nov 02, 2025

Nov 01, 2025

Is Zenas BioPharma Inc. stock ready for breakoutQuarterly Portfolio Review & High Conviction Trade Alerts - newser.com

Nov 01, 2025

Leading vs lagging indicators on Zenas BioPharma Inc. performanceJuly 2025 Outlook & Daily Growth Stock Investment Tips - newser.com

Nov 01, 2025

Oct 31, 2025

Citigroup Raises Zenas BioPharma (NASDAQ:ZBIO) Price Target to $46.00 - MarketBeat

Oct 31, 2025

Zenas BioPharma, Inc.Common Stock (Nasdaq:ZBIO) Stock Quote - FinancialContent

Oct 31, 2025

Weiss Ratings Reiterates Sell (E+) Rating for Zenas BioPharma (NASDAQ:ZBIO) - MarketBeat

Oct 31, 2025

HC Wainwright Reduces Earnings Estimates for Zenas BioPharma - MarketBeat

Oct 31, 2025

Strategies to average down on Zenas BioPharma Inc.Insider Selling & Technical Entry and Exit Tips - newser.com

Oct 31, 2025

Published on: 2025-10-31 01:53:58 - newser.com

Oct 31, 2025

Oct 30, 2025

Zenas BioPharma (NASDAQ:ZBIO) Shares Down 7.3%Here's What Happened - MarketBeat

Oct 30, 2025

Is Zenas BioPharma Inc a good long term investmentPortfolio Allocation Tips & Free Phenomenal Trading Returns - earlytimes.in

Oct 30, 2025

Zenas BioPharma (ZBIO) Price Target Increased by 21.59% to 40.22 - MSN

Oct 30, 2025

Promising Phase 2 Results and Strategic Licensing Drive Buy Rating for Zenas BioPharma - TipRanks

Oct 30, 2025

Oct 29, 2025

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat

Oct 29, 2025

Oct 28, 2025

Zenas BioPharma (NASDAQ:ZBIO) Given Outperform Rating at Wedbush - MarketBeat

Oct 28, 2025

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Oct 28, 2025

ZBIO: Citigroup Raises Price Target, Maintains Buy Rating | ZBIO Stock News - GuruFocus

Oct 28, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zenas BioPharma, Inc. (ZBIO) And Encourages Stockholders to Reach Out - ACCESS Newswire

Oct 28, 2025

ZBIO: Morgan Stanley Raises Price Target, Maintains Overweight R - GuruFocus

Oct 28, 2025